MBTPS2 and osteogenesis imperfecta: With the identification of more MBTPS2-OI patients and their molecular characterization via multiple omics approaches in future, the molecular signature of this disease will be fine-tuned to better understand the disease path mechanisms and prove the pathogenicity of novel genetic variants.